Skip to main navigation Skip to search Skip to main content

Phase I study of tandem high-dose chemotherapy with autologous peripheral blood stem cell rescue for children with recurrent brain tumors: A pediatric blood and marrow transplant consortium study

  • Andrew L. Gilman
  • , Chad Jacobsen
  • , Nancy Bunin
  • , John Levine
  • , Fred Goldman
  • , Anne Bendel
  • , Michael Joyce
  • , Peter Anderson
  • , Marta Rozans
  • , Donna A. Wall
  • , Tobey J. Macdonald
  • , Steve Simon
  • , Richard P. Kadota
  • Levine Children’s Hospital
  • The Children's Hospital of Philadelphia
  • University of Michigan, Ann Arbor
  • Children's Health System
  • Children's Hospitals and Clinics of Minnesota
  • University of Texas MD Anderson Cancer Center
  • St. Christopher's Hospital for Children
  • Cancer Care Manitoba
  • Children's Healthcare of Atlanta
  • Children's Mercy Hospitals and Clinics
  • Rady Children's Hospital

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Abstract

Background: High-dose chemotherapy with autologous stem cell rescue (HDC/SCR) has produced responses and prolonged survival for some children with recurrent brain tumors, but is associated with considerable morbidity and mortality. A Phase I trial of two cycles of HDC/SCR for recurrent brain tumors in children was performed to determine the maximum tolerated doses for a novel regimen. Procedures: Two cycles of HDC/SCR were given. Cycle 1 included thiotepa and carmustine given on days -5, -4, and -3. Four to six weeks later, patients received cycle 2 which included thiotepa and carboplatin given on days -5, -4, and -3. Autologous peripheral blood stem cells (PBSC) were infused on day 0 of each cycle. Results: Thirty-two patients were treated and 25 patients received both cycles of HDC/SCR. Common toxicities included mucositis, emesis, diarrhea, anorexia, and pancytopenia. Eight of 32 (25%) assessable children died from regimen-related toxicity. Pulmonary failure occurred in seven patients. Seven patients had grade 3-4 neurotoxicity. The 3-year event-free survival (EFS) was 25%. Conclusions: We determined the maximum tolerated regimen to be thiotepa 600mg/m2 and carmustine 300mg/m2 followed by thiotepa 600mg/m2 and carboplatin 1,200mg/m2. Pulmonary toxicity was considerable. The toxic death rate was similar to other trials of HDC/SCR for children with recurrent brain tumors performed during the same time period. The regimen resulted in prolonged time to progression for a significant number of patients and long-term survival for some patients with recurrent medulloblastoma and rhabdoid tumor.

Original languageEnglish
Pages (from-to)506-513
Number of pages8
JournalPediatric Blood and Cancer
Volume57
Issue number3
DOIs
StatePublished - Sep 2011

Keywords

  • Brain tumors
  • Myeloablative therapy
  • Phase I clinical trials
  • Stem cell transplantation

Fingerprint

Dive into the research topics of 'Phase I study of tandem high-dose chemotherapy with autologous peripheral blood stem cell rescue for children with recurrent brain tumors: A pediatric blood and marrow transplant consortium study'. Together they form a unique fingerprint.

Cite this